STML Insider Trading Activity and SEC Form 4 Filings
STML insider trading summary
No open-market insider purchases or sales of Stemline Therapeutics Inc (STML) have been reported on SEC Form 4 in the past 12 months.
Latest STML insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 4, 2020 | Robert Francomano | Chief Commercial Officer | Sell | $3K (272 @ $11.51) |
| Apr 15, 2020 | Ivan Bergstein | Chief Executive Officer | Sell | $262K (53,618 @ $4.88) |
| Apr 1, 2020 | David Gionco | Chief Accounting Officer | Sell | $55K (11,524 @ $4.79) |
| Mar 16, 2020 | David Gionco | Chief Accounting Officer | Sell | $11K (2,849 @ $3.88) |
| Mar 10, 2020 | David Gionco | Chief Accounting Officer | Sell | $44K (8,846 @ $4.92) |
| Mar 10, 2020 | Kenneth Hoberman | Chief Operating Officer | Sell | $82K (16,704 @ $4.91) |
| Mar 10, 2020 | Ivan Bergstein | Chief Executive Officer | Sell | $180K (36,542 @ $4.92) |
| Mar 9, 2020 | David Gionco | Chief Accounting Officer | Sell | $25K (5,011 @ $5.08) |
| Mar 9, 2020 | Kenneth Hoberman | Chief Operating Officer | Sell | $48K (9,487 @ $5.08) |
| Mar 9, 2020 | Ivan Bergstein | Chief Executive Officer | Sell | $106K (20,909 @ $5.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.